



(51) International Patent Classification:

C07F 9/6515 (2006.01) C07F 9/38 (2006.01)
C07F 9/6524 (2006.01) A61K 51/04 (2006.01)
C07F 9/655 (2006.01) C07D 405/12 (2006.01)
C07F 9/6558 (2006.01) C07D 401/12 (2006.01)
C07F 9/6561 (2006.01) C07K 5/062 (2006.01)

(21) International Application Number:

PCT/EP2024/080350

(22) International Filing Date:

25 October 2024 (25.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23206564.9	27 October 2023 (27.10.2023)	EP
24167036.3	27 March 2024 (27.03.2024)	EP
24206215.6	11 October 2024 (11.10.2024)	EP

(71) Applicant: **PHILOCHEM AG** [CH/CH]; Libernstrasse 3,
8112 Otelfingen (CH).


(72) Inventors: **CAZZAMALLI, Samuele**; c/o Philochem AG, Libernstrasse 3, 8112 Otelfingen (CH). **GEORGIEV, Tony**; c/o Philochem AG, Libernstrasse 3, 8112 Otelfingen (CH). **OEHLER, Sebastian**; c/o Philochem AG, Libernstrasse 3, 8112 Otelfingen (CH). **MIGLIORINI, Francesca**; c/o Philochem AG, Libernstrasse 3, 8112 Otelfingen (CH). **NERI, Dario**; c/o Philochem AG, Libernstrasse 3, 8112 Otelfingen (CH). **PARK KIM, Young Seo**; c/o Philochem AG, Libernstrasse 3, 8112 Otelfingen (CH).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ACID PHOSPHATASE 3 LIGANDS FOR TARGETED DELIVERY APPLICATIONS

FIG. 26



(57) Abstract: The present invention relates to ligands against Acid Phosphatase 3 (ACP3 or ACP3), also known as Prostatic Acid Phosphatase (PAP). Selective ACP3 ligands may be able to exclusively interact with antigens expressed on the surface of tumor cells for in vivo pharmaco-delivery applications. The ligand may display very high affinity and selectivity towards ACP3 to enable targeted delivery of a payload, including therapeutic and diagnostic payloads, to a site afflicted by or at risk of a disease characterized by the expression of ACP3.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

02 January 2026 (02.01.2026)